Literature DB >> 34264565

Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response.

Christina A Nelson, Dana Meaney-Delman, Shannon Fleck-Derderian, Katharine M Cooley, Patricia A Yu, Paul S Mead.   

Abstract

This report provides CDC recommendations to U.S. health care providers regarding treatment, pre-exposure prophylaxis, and postexposure prophylaxis of plague. Yersinia pestis, the bacterium that causes plague, leads to naturally occurring disease in the United States and other regions worldwide and is recognized as a potential bioterrorism weapon. A bioweapon attack with Y. pestis could potentially infect thousands, requiring rapid and informed decision making by clinicians and public health agencies. The U.S. government stockpiles a variety of medical countermeasures to mitigate the effects of a bioterrorism attack (e.g., antimicrobials, antitoxins, and vaccines) for which the 21st Century Cures Act mandates the development of evidence-based guidelines on appropriate use. Guidelines for treatment and postexposure prophylaxis of plague were published in 2000 by a nongovernmental work group; since then, new human clinical data, animal study data, and U.S. Food and Drug Administration approvals of additional countermeasures have become available. To develop a comprehensive set of updated guidelines, CDC conducted a series of systematic literature reviews on human treatment of plague and other relevant topics to collect a broad evidence base for the recommendations in this report. Evidence from CDC reviews and additional sources were presented to subject matter experts during a series of forums. CDC considered individual expert input while developing these guidelines, which provide recommended best practices for treatment and prophylaxis of human plague for both naturally occurring disease and following a bioterrorism attack. The guidelines do not include information on diagnostic testing, triage decisions, or logistics involved in dispensing medical countermeasures. Clinicians and public health officials can use these guidelines to prepare their organizations, hospitals, and communities to respond to a plague mass-casualty event and as a guide for treating patients affected by plague.

Entities:  

Year:  2021        PMID: 34264565     DOI: 10.15585/mmwr.rr7003a1

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  4 in total

1.  Yersinia pestis antibiotic resistance: a systematic review.

Authors:  Chen Lei; Suresh Kumar
Journal:  Osong Public Health Res Perspect       Date:  2022-02-18

2.  Evaluation of a Frozen Micro-Agar Plates of MAPt Antibiotic Susceptibility Test for Enhanced Bioterror Preparedness.

Authors:  Shahar Rotem; Ohad Shifman; Ronit Aloni-Grinstein
Journal:  Antibiotics (Basel)       Date:  2022-04-26

3.  Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague.

Authors:  Yaron Vagima; David Gur; Moshe Aftalion; Sarit Moses; Yinon Levy; Arik Makovitzki; Tzvi Holtzman; Ziv Oren; Yaniv Segula; Ella Fatelevich; Avital Tidhar; Ayelet Zauberman; Shahar Rotem; Emanuelle Mamroud; Ida Steinberger-Levy
Journal:  Viruses       Date:  2022-03-26       Impact factor: 5.818

4.  Development of a dual antigen lateral flow immunoassay for detecting Yersinia pestis.

Authors:  Derrick Hau; Brian Wade; Chris Lovejoy; Sujata G Pandit; Dana E Reed; Haley L DeMers; Heather R Green; Emily E Hannah; Megan E McLarty; Cameron J Creek; Chonnikarn Chokapirat; Jose Arias-Umana; Garett F Cecchini; Teerapat Nualnoi; Marcellene A Gates-Hollingsworth; Peter N Thorkildson; Kathryn J Pflughoeft; David P AuCoin
Journal:  PLoS Negl Trop Dis       Date:  2022-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.